Septerna, Inc. priced its initial public offering at $18.00 a share, offering 16,000,000 shares of common stock, to list on the Nasdaq Global Market. It filed a Form S-1 registration statement for an initial public offering on October 2, 2024. As of November 6, 2026, its final prospectus is on file (Form 424B4, October 25, 2024).
Sell to companies like Septerna, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Septerna, Inc. filed a Form S-1 registration statement for an initial public offering on 2024-10-02. It has amended it 2 times. It filed its final prospectus on 2024-10-25, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Septerna, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 11.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by DRIEHAUS CAPITAL MANAGEMENT LLC | 9.83% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 3.8% of the class | 5%+ stakes | Source |
Check before you invest in Septerna, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Septerna, Inc. and the records around it.
Septerna, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- DRIEHAUS CAPITAL MANAGEMENT LLC also filed stake reports on 16 other companies: Cardinal Infrastructure Group Inc. (Aug 2026), Cue Biopharma, Inc. (Aug 2026), Definium Therapeutics, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Also filing to list on the Nasdaq Global Market
IPO filings on the Nasdaq Global Market in Q4 2024, newest first.
- Nature's Miracle Holding Inc. (Nov 2024)
Watch Septerna, Inc.
Get an email when Septerna, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Septerna, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Septerna, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Septerna, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock has been approved for listing on the Nasdaq Global Market under the symbol of SEPN.From the 424B4 filed 2024-10-25
Shares offered
We are offering 16,000,000 shares of our common stock.From the 424B4 filed 2024-10-25
Offering price
The initial public offering price per share is $18.00.From the 424B4 filed 2024-10-25
Use of proceeds
We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents, and marketable securities, as follows: approximately $117 million to advance the continued development of SEP-786, our lead product candidate from our PTH1R program through completion of a Phase 2 clinical trial in hypoparathyroidism patients and initiation of a Phase 3 clinical trial, and additional molecules targeting PTH1R; approximately $37 million to advance the development of SEP-631 through completion of a Phase 1 clinical trial and initiation of Phase 2 clinical studies, and additional small molecules within our MRGPRX2 program; approximately $57 million for other…From the 424B4 filed 2024-10-25
Revenue
Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023.From the S-1/A filed 2024-10-24
Net loss or income
Our net loss was $27.7 million for the year ended December 31, 2022 and net income was $4.2 million for the year ended December 31, 2023.From the S-1/A filed 2024-10-24
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-10-02 | Registration statement filed | S-1 |
| 2024-10-21 | Registration statement amended | S-1/A |
| 2024-10-24 | Registration statement amended | S-1/A |
| 2024-10-25 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Septerna, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.